Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their over-allotment option to purchase an additional 1,500,000 shares of common stock at the public offering price of $3.15 per share. Proceeds from the exercise of the option will be approximately $4.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The closing of the over-allotment option exercise is expected to occur on May 23, 2011, subject to customary closing conditions.
